Skip to content
AwardedSpainGoods€152,292,577

Suministro de forma centralizada de medicamentos de uso humano para el tratamiento de la fibrosis quística que contiene los principios activos siguientes: IVACAFTOR, LUMACAFTOR + IVACAFTOR, TEZACAFTOR + IVACAFTOR Y LEXACAFTOR + IVACAFTOR +TEZACAFTOR con destino a los centros del ámbito de la sanidad pública valenciana.

Published
Published 24 June 2026

Overview

The Valencian Public Health Authority has awarded a centralized supply contract for cystic fibrosis medications containing ivacaftor, lumacaftor + ivacaftor, tezacaftor + ivacaftor, and lexacaftor + ivacaftor + tezacaftor to Vertex Pharmaceuticals Spain SL. The contract, valued at approximately 152.3 million EUR, supplies these pharmaceutical products to public healthcare facilities across the Valencia region.

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€152,292,577
Procedure
Direct
Published
24 June 2026
Classification (CPV)
Medical equipments, pharmaceuticals and personal care productsMedicinal products for the respiratory system

Award outcome

Awarded value
€0
Award date
21 May 2026
Winner
  • Vertex Pharmaceuticals Spain SL,

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    24 June 2026

Contracting authority

  • Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad

    Procuring entity

    Valencia, Spain

    ID_PLATAFORMA: 20897030133463

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Suministro de forma centralizada de medicamentos de uso humano para el tratamiento de la fibrosis quística que contiene los principios activos siguientes: IVACAFTOR, LUMACAFTOR + IVACAFTOR, TEZACAFTOR + IVACAFTOR Y LEXACAFTOR + IVACAFTOR +TEZACAFTOR con destino a los centros del ámbito de la sanidad pública valenciana. — won by Vertex Pharmaceuticals Spain SL, — Skim